Showing results (231-240 of 2,409) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|November 22, 2019
Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centersRichard W Joseph, Alicia C Shillington, Todd A Lee, et al.Journal of Medical Economics|November 6, 2019
Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopagBeilei Cai, Qayyim Said, Xin Li, et al.Journal of Medical Economics|December 15, 2019
Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new modelsT A Rautenberg, G George, M B Bwana, et al.Journal of Medical Economics|March 10, 2020
Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database studyCeline Miyazaki, Rosarin Sruamsiri, Jörg Mahlich, et al.Journal of Medical Economics|December 8, 2018
An economic evaluation of perioperative enteral nutrition in patients undergoing colorectal surgery (SANICS II study)Madhuri Pattamatta, Silvia M A A Evers, Boudewijn J J Smeets, et al.Journal of Medical Economics|January 16, 2019
Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in FinlandPetri Mankinen, Ville Vihervaara, Saku Torvinen, et al.Journal of Medical Economics|January 17, 2019
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in ChinaWeiting Liao, Jiaxing Huang, David Hutton, et al.Journal of Medical Economics|November 5, 2019
Current treatment patterns and medical costs for multiple myeloma in Japan: a cross-sectional analysis of a health insurance claims databaseShuji Uno, Rei Goto, Kenshi Suzuki, et al.Journal of Medical Economics|January 31, 2020
Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with heminBarbara Blaylock, Josh Epstein, Paul SticklerJournal of Medical Economics|January 29, 2020
Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysisB B Hansen, S Nuhoho, S N Ali, et al.Pageof 241